Role of vandetanib in the management of medullary thyroid cancer

References

• KouvarakiMAShapiroSEPerrierNDRET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumorsThyroid200515653154416029119
   PubMed Web of Science ®Google Scholar
• RomanSLinRSosaJAPrognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 casesCancer200610792134214217019736
   PubMed Web of Science ®Google Scholar
• PhayJEShahMHTargeting RET receptor tyrosine kinase activation in cancerClin Cancer Res201016245936594120930041
   PubMed Web of Science ®Google Scholar
• EngCRET proto-oncogene in the development of human cancerJ Clin Oncol199917138039310458257
   PubMed Web of Science ®Google Scholar
• HofstraRMLandsvaterRMCeccheriniIA mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinomaNature199436764613753767906866
   PubMed Web of Science ®Google Scholar
• MulliganLMKwokJBHealeyCSGerm-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2ANature199336364284584608099202
   PubMed Web of Science ®Google Scholar
• CappCWajnerSMSiqueiraDRBrasilBAMeurerLMaiaALIncreased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinomaThyroid201020886387120615131
   PubMed Web of Science ®Google Scholar
• GómezKVargheseJJimenezCMedullary thyroid carcinoma: molecular signaling pathways and emerging therapiesJ Thyroid Res2011201181582621687607
   PubMedGoogle Scholar
• Rodriguez-AntonaCPallaresJMontero-CondeCOverexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasisEndocr Relat Cancer201017171619776290
   PubMed Web of Science ®Google Scholar
• PapottiMOliveroMVolanteMExpression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroidEndocr Pathol2000111193012114654
   PubMed Web of Science ®Google Scholar
• ShermanSITargeted therapies for thyroid tumorsMod Pathol201124Suppl 2S44S5221455200
   PubMed Web of Science ®Google Scholar
• KnowlesPPMurray-RustJKjaerSStructure and chemical inhibition of the RET tyrosine kinase domainJ Biol Chem200628144335773358716928683
   PubMed Web of Science ®Google Scholar
• CarlomagnoFGuidaTAnagantiSDisease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsOncogene200423366056606315184865
   PubMed Web of Science ®Google Scholar
• CarlomagnoFGuidaTAnagantiSIdentification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474Endocr Relat Cancer200916123324119029224
   PubMed Web of Science ®Google Scholar
• WedgeSROgilvieDJDukesMZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationCancer Res200262164645465512183421
   PubMed Web of Science ®Google Scholar
• CarlomagnoFVitaglianoDGuidaTZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinasesCancer Res200262247284729012499271
   PubMed Web of Science ®Google Scholar
• BroutinSDupuyCCaillouBIn vitro and in vivo activity of vandetanib in a human medullary thyroid carcinoma model bearing a RETC634W activating mutationProceedings of the American Association for Cancer Research2009Denver, CO
   Google Scholar
• VitaglianoDDe FalcoVTamburrinoAThe tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cellsEndocr Relat Cancer201118111120943719
   PubMed Web of Science ®Google Scholar
• McCartyMFWeyJStoeltzingOZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancerMol Cancer Ther2004391041104815367698
   PubMed Web of Science ®Google Scholar
• ConradCIschenkoIKohlGAntiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor modelAnticancer Drugs200718556957917414626
   PubMed Web of Science ®Google Scholar
• DrevsJKonerdingMAWolloscheckTThe VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinomaAngiogenesis20047434735415886878
   PubMedGoogle Scholar
• WuWOnnAIsobeTTargeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockadeMol Cancer Ther20076247148317308046
   PubMed Web of Science ®Google Scholar
• CheckleyDTessierJJKendrewJWatertonJCWedgeSRUse of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumoursBr J Cancer200389101889189514612898
   PubMed Web of Science ®Google Scholar
• BradleyDPTessierJTCheckleyDRKuribayashiHWedgeSRThe VEGF signaling inhibitors ZD6474 and AZD2171 compromise hemodynamic parameters in an SW620 human colon tumor model: An analysis using perfusion-permeability dynamic contrast-enhanced magnetic resonance imaging (pp-DCE-MRI)AACR Meeting Abstracts2004200414552
   Google Scholar
• WalterMABenzMRHildebrandtIJMetabolic imaging allows early prediction of response to vandetanibJ Nucl Med201152223124021233183
   PubMed Web of Science ®Google Scholar
• VerbeekHHAlvesMMde GrootJWThe effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cellsJ Clin Endocrinol Metab2011966E991E99521470995
   PubMed Web of Science ®Google Scholar
• HoldenSNEckhardtSGBasserRClinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumorsAnn Oncol20051681391139715905307
   PubMed Web of Science ®Google Scholar
• TherassePMeasuring the clinical response. What does it mean?Eur J Cancer200238141817182312204662
   PubMed Web of Science ®Google Scholar
• TamuraTMinamiHYamadaYA phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumorsJ Thorac Oncol2006191002100917409986
   PubMed Web of Science ®Google Scholar
• ZhangLLiSZhangYPharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose studyClin Ther201133331532721600385
   PubMed Web of Science ®Google Scholar
• WellsSAJrGosnellJEGagelRFVandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Oncol201028576777220065189
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• RobinsonBGPaz-AresLKrebsAVasselliJHaddadRVandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Endocrinol Metab20109562664267120371662
   PubMed Web of Science ®Google Scholar
• WellsSAJrRobinsonBGGagelRFVandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialJ Clin Oncol201230213414122025146
   PubMed Web of Science ®Google Scholar
• CabanillasMEHuMIDurandJBBusaidyNLChallenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancerJ Thyroid Res2011201198578022007339
   PubMedGoogle Scholar
• DuplombSBenoitAMechtouff-CimarelliLUnusual adverse event with vandetanib in metastatic medullary thyroid cancerJ Clin Oncol2012302e21e2322162581
   PubMed Web of Science ®Google Scholar
• YehSFineHASmithJACorneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytomaCornea200928669970219512898
   PubMed Web of Science ®Google Scholar
• BrassardMNeraudBTrabadoSEndocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancerJ Clin Endocrinol Metab20119692741274921715537
   PubMed Web of Science ®Google Scholar
• AbdulrahmanRMVerloopHHoftijzerHSorafenib-induced hypothyroidism is associated with increased type 3 deiodinationJ Clin Endocrinol Metab20109583758376220484486
   PubMed Web of Science ®Google Scholar
• AstraZenecaVandetanib (ZD6474) tabletsOncologic Drugs Advisory Committee (ODAC) Meeting Briefing Document1222010 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM235092.pdfAccessed on December 30, 2011
   Google Scholar
• DeshpandeHRomanSThumarJSosaJAVandetanib (ZD6474) in the treatment of medullary thyroid cancerClin Med Insights Oncol2011521322121836817
   PubMedGoogle Scholar